<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        16-116-83
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1983
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RETARPEN 1.2MEGA U.WITH SOLVENT
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BENZATHINE PENICILLIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1200000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        6.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SANDOZ" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01CE08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Retarpen is an antibiotic. It contains the active substance called benzathine benzylpenicillin. It belongs to a family of medicines called &ldquo;penicillins&rdquo;. It works by killing certain bacteria which can cause infections.</p><p>&nbsp;</p><p>Retarpen is used for the treatment of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erysipelas (skin infection)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Syphilis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tropical infectious diseases of the skin, caused by bacteria of the <em>Treponema </em>species, such as yaws, or pinta</p><p>&nbsp;</p><p>Retarpen is also used to prevent the following diseases:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rheumatic fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; poststreptococcal glomerulonephritis (a specific form of kidney inflammation)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erysipelas (skin infection)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Retarpen 600,000/1.2 /2.4 MIU</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to the active substance benzathine benzylpenicillin, other penicillins, soya, peanut or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had an allergic reaction to any antibiotic. This can include a skin rash or&nbsp; swelling of the face or neck.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist or nurse before using Retarpen:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had any allergic reactions to other antibiotics like penillicin or other beta-lactam antibiotics,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney problems (your doctor may need to adapt the dose of this medicine),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are on a controlled sodium diet</p><p>&nbsp;</p><p>Retarpen should not be used in tissues with poor blood flow.</p><p>&nbsp;</p><p>If allergic symptoms occur (e.g. skin rash, itching, shortness of breath), tell a doctor immediately. Before treatment, a hypersensitivity test should be performed if possible. If an allergic reaction&nbsp;&nbsp; occurs, your doctor will stop your treatment and, if necessary, start appropriate therapy.</p><p>&nbsp;</p><p>As a possible cross-allergy should be considered in patients with hypersensitivity to cephalosporins, please tell your doctor if you have already had a previous allergic reaction to certain antibiotics (cephalosporins).</p><p>&nbsp;</p><p>If you have already been diagnosed with an allergy and/or allergic asthma or hay fever, you should tell your doctor. Severe immediate allergic reactions are possible even when the drug is administered for the first time. Based on general principles, in particular in some cases, you will remain under observation for at least half an hour after the medicine has been administered in case an acute allergic reaction should occur. If an allergy occurs, the doctor will take appropriate measures. Treatment with</p><p>Retarpen must be stopped immediately.</p><p>&nbsp;</p><p>When treating syphilis, a bodily reaction to the bacterial toxins may occur, which lasts up to several days (Jarisch-Herxheimer reaction, see section 4). Typical symptoms are sudden fever (sometimes with chills), pallor - followed by skin redness, headache, painful muscles and joints or tiredness. To suppress or alleviate a Jarisch-Herxheimer reaction, your doctor will start appropriate therapy.</p><p>&nbsp;</p><p>Dose adjustments are necessary in patients with impaired kidney function and in patients with impaired liver function (see section 3).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>In long-term treatment (more than 5 days), your doctor may arrange for checks on your blood count and kidney function tests. Please make sure that you attend the check-ups prescribed by the doctor.</p><p>&nbsp;</p><p>As with other antibiotics, therapy with Retarpen may also lead to the overgrowth of non-susceptible germs. Contact your doctor if you get e.g. a fungal infection.</p><p>&nbsp;</p><p>During treatment with antibiotics, including Retarpen, diarrhea may occur, even several weeks after you stopped your therapy. In case of severe or persistent diarrhea, or if you notice that your stools contain blood or mucus, contact your doctor immediately. The therapy with Retarpen must be stopped immediately, as it can be life-threatening. Do not take any medication which stop or slow down the bowel movements.</p><p>&nbsp;</p><p>If neurological involvement cannot be ruled out in patients with congenital syphilis, forms of penicillin that reach a higher level in cerebrospinal fluid should be used.</p><p>&nbsp;</p><p>Decreased elimination of povidone (one excipient included in this drug) should be considered in case of impairment of renal function.It cannot be excluded that in very rare cases to an accumulation of povidone or a local deposition and formation of granulomas may occur, which may be confused with tumors.</p><p>&nbsp;</p><p>An effect on diagnostic laboratory procedures should also be considered (see also section 4).</p><p>&nbsp;</p><p>Other medicines and Retarpen 600,000/1.2 /2.4 MIU</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Caution should be exercised when administering Retarpen at the same time as the following medicines:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; probenecid, a medicine used to treat gout.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methotrexate, a medicine used in chemotherapy. The combination with methotrexate is not recommended.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anticoagulants: medicines used to thin the blood.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before this medicine is used.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>Retarpen can be used during pregnancy after appropriate diagnosis and careful consideration of the benefits and risks by the prescribing doctor.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Small amounts of benzylpenicillin, the active substance, pass into breast milk.</p><p>Although no side effects have been reported to date in young infants fed on breast milk, the&nbsp; possibility of sensitisation or interference with the intestinal flora must nevertheless be considered. In the case of occurrence of diarrhoea, candidosis or rash in the child, ask immediately your doctor who will give you an advice, because these disorders in the child could be due to Retarpen.</p><p>&nbsp;</p><p>In young infants also being fed on baby food, mothers receiving Retarpen should express and discard their breast milk. They can start breast-feeding again 24 hours after completion of treatment.</p><p>&nbsp;</p><p>&nbsp;</p><p>Driving and using machines</p><p>This medicine can impair responsiveness and the ability to drive.</p><p>Due to the occurrence of possible serious side effects (e.g. anaphylactic shock with collapse and anaphylactoid reactions, see section 4), Retarpen can have a major influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>Retarpen 600,000/1.2/2.4 MIU contains phospholipids from the soyabeans</p><p>If you are allergic to peanut or soya, this medicinal product should not be used.</p><p>&nbsp;</p><p><strong>Retarpen 600,000 IU/1.2 MIU contains less than 1 mmol sodium (23 mg) per dose</strong>, that is to say essentially &lsquo;sodium-free&rsquo; and can be used by patients who are on sodium controlled diet.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Retarpen 2.4 MIU contains 40.1 mg sodium </strong>(main component of cooking/table salt) <strong>per dose</strong>. This is equivalent to 2% of the recommended maximum daily dietary intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>In principle, Retarpen is administered by a health practitioner. The recommended dose is:</strong></p><p><u>General treatment:</u></p><p>Adults and adolescents:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.2&nbsp; MIU once weekly Children &gt; 30 kg body weight: 1.2 MIU once weekly Children &lt; 30 kg body weight: 600,000 IU once weekly Duration of treatment:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; single dose</p><p>&nbsp;</p><p><u>Treatment of syphilis:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Primary and secondary stage</p><p>Adults and adolescents:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 x 2.4 MIU</p><p>Children:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50,000 IU/kg body weight, however not more than 2.4 MIU</p><p>&nbsp;</p><p>&nbsp;</p><p>(If clinical symptoms return or laboratory findings remain strongly positive, treatment should be repeated.)</p><p>Duration of treatment:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; single dose</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Late-stage syphilis (latent seropositive syphilis) Adults and adolescents:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.4 MIU once weekly</p><p>Children:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50,000 IU/kg body weight, however not more than 2.4 MIU</p><p>Duration of treatment:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3 weeks</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of congenital syphilis: without neurological involvement Newborns and infants:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 x 50,000 IU/kg body weight</p><p>Duration of treatment:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; single dose</p><p>&nbsp;</p><p><u>Treatment of tropical infectious skin diseases (yaws, pinta): </u>Adults and adolescents:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 x 1.2 MIU</p><p>Children &gt; 30 kg body weight: 1 x 1.2 MIU Children &lt; 30 kg body weight: 1 x 600,000 IU Duration of treatment:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; single dose</p><p>&nbsp;</p><p><u>Prevention of rheumatic fever, poststreptococcal glomerulonephritis and erysipelas: </u>Adults and adolescents:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 x 1.2 MIU every 3-4 weeks</p><p>Children &gt; 30 kg body weight:&nbsp;&nbsp; 1 x 1.2 MIU every 3-4 weeks</p><p>Children &lt; 30 kg body weight: 1 x 600,000 IU every 3-4 weeks Duration of treatment:</p><p>a)&nbsp; without heart involvement: at least 5 years, or up to 21 years of age</p><p>b)&nbsp; temporary heart involvement: at least 10 years, or up to 21 years of age</p><p>c)&nbsp; persistent heart involvement: at least 10 years or up to 40 years of age; life-long treatment is sometimes necessary.</p><p>&nbsp;</p><p>Special patient groups (impaired kidney function or impaired liver function)</p><p>The dosage and dosing interval will be determined by your doctor. If you have any questions on your dosage, please contact your doctor.</p><p>&nbsp;</p><p>Method of administration</p><p>The preparation may only be injected into muscle (intramuscular administration).</p><p>&nbsp;</p><p>The injection must <u>not </u>be administered into tissue with poor blood flow.</p><p>In case of repeated intramuscular application, the site of injection site must be changed.</p><p>&nbsp;</p><p>Severe local reactions may occur during intramuscular administration, especially in young children. For this reason, other treatments such as a different penicillin formulation can be used where possible.</p><p>&nbsp;</p><p>If you have been given more Retarpen than you should have been given</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>At extremely high doses, penicillins can cause neuromuscular excitability or epileptiform seizures. If overdose is suspected, tell a doctor immediately for advice.</p><p>&nbsp;</p><p>If it was forgotten to give you Retarpen</p><p>If you think that you have not been given a dose, talk to your doctor immediately.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Very common:&nbsp; may affect more than 1 in 10 people</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; may affect up to 1 in 10 people</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; may affect up to 1 in 100 people Rare:&nbsp;&nbsp;&nbsp;&nbsp; may affect up to 1 in 1,000 people Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; may affect up to 1 in 10,000 people</p><p>Not known:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; frequency cannot be estimated from the available data</p><p>&nbsp;</p><p><strong>Infections and infestations</strong></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fungal infection (candidiasis)</p><p>&nbsp;</p><p><strong>Blood and lymphatic system disorders</strong></p><p>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain blood disorders (so-called haemolytic anaemia, leukopenia, thrombocytopenia, agranulocytosis)</p><p>&nbsp;</p><p><strong>Immune system disorders</strong></p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions: nettle rash (urticaria), angioedema (swelling), skin reactions (erythema multiforme, exfoliative dermatitis), fever, painful joints, anaphylactic shock with collapse and anaphylactoid reactions (asthma, skin bleeding known as purpura, gastrointestinal complaints).</p><p>Not known:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serum sickness. When treating syphilis, a Jarisch-Herxheimer reaction may occur as a result of bacteriolysis, characterised by fever, chills, general and focal symptoms. In patients with dermatomycosis (skin fungus), para-allergic reactions may occur,<em>:</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><strong>Gastrointestinal disorders</strong></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea, nausea</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the mouth lining (stomatitis) and burning tongue (glossitis), vomiting Not known:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pseudomembranous colitis (see also section 2).</p><p>&nbsp;</p><p><strong>Hepatobiliary disorders</strong></p><p>Not known:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver inflammation (hepatitis), impairment of bile flow (cholestasis)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Renal and urinary disorders</strong></p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney disease (nephropathy), kidney inflammation (interstitial nephritis)</p><p>&nbsp;</p><p><strong>General disorders and administration site conditions</strong></p><p>Unknown<em>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>pain at the injection site, injection site infiltrates</p><p>&nbsp;</p><p><strong>Investigations</strong></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in certain tests and investigations, such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; positive direct Coombs&rsquo; test.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; false-positive tests to determine protein in the urine, using precipitation techniques (Folin-Ciocalteu-Lowry method, biuret method).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; false-positive tests to determine protein in the urine (ninhydrin method).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; simulation of pseudobisalbuminaemia when using electrophoresis methods to determine albumin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; false-positive non-enzymatic tests to detect glucose in the urine and urobilinogen.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels when determining 17-ketosteroids in urine (using the Zimmermann reaction) (see section 2).</p><p>&nbsp;</p><p>&nbsp;</p><p>It cannot be ruled out that, in very rare cases and due to the povidone content, povidone may accumulate in the reticuloendothelial system (RES) or local deposits and foreign body granuloma may occur, which may be confused with tumors.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label, carton and container after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp; Store below 25 &deg;C.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is benzathine benzylpenicillin.</p><p>&nbsp;</p><p>Retarpen 600,000/1.2 /2.4 MIU powder and solvent for suspension for injection contains 600,000/1.2 mio./2.4 mio. IU benzathine benzylpenicillin (phospholipids from the soya beans).</p><p>&nbsp;</p><p>The other ingredients are: Povidone, simethicone, sodium citrate, mannitol (E421). 1 vial of solvent contains 5 ml water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                White to cream-coloured powder and solvent for suspension for injection.

5/5/15 ml clear glass vial, type III (Ph.Eur.), closed with halogenated butyl rubber stopper and aluminum cap.
Solvent: Plastic vial made from polyethylene, nominal capacity 5 ml. Packs with 1x powder and solvent for suspension for injection.
Packs with 1x or 100x powder and solvent for suspension for injection.
Packs with 1x or 50 x powder and solvent for suspension for injection. Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sandoz GmbH,</p><p>6250 Kundl,</p><p>Austria</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                07/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يُعد عقار ريتاربين مضادًّا حيويًّا. ويحتوي على مادة فعّالة تُسمى بنزاثين بنزل بنيسيللين. ينتمي العقار إلى فئة أدوية تُسمى &quot;البنسيلينات&quot;. ويعمل من خلال القضاء على بكتيريا معينة يمكنها أن تسبب العدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم عقار ريتارابين في علاج:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحُمْرَة (عدوى جلدية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض الزهري.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأمراض الجلدية المعدية المدارية، التي تنتج عن بكتيريا من سلالة <em>اللولبيات</em>، مثل المرض العليقي أو مرض بنتا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كما يُستخدم عقار ريتاربين لمنع الإصابة بالأمراض التَّالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى الروماتيزمية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب كبيبات الكُلى التَّالِي للعِقْدِيَّات (شكل معين من أشكال التهاب الكُلى).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحُمْرَة (عدوى جلدية).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم عقار ريتاربين ٦٠٠٠٠٠/١.٢/٢.٤ مليون وحدة دولية في الحالات التَّالية</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه المادة الفعالة بنزاثين بنزل بنيسيللين أو بنسيلينات أخرى أو الصويا أو السوداني أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أُصِبت من قبل بتفاعل حساسية تجاه أي مضاد حيوي. قد يشمل هذا طفحًا جلديًّا أو تورمًا بالوجه أو الرقبة.</p><p dir="RTL">&nbsp;</p><p>تحذيرات واحتياطات</p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي أو الممرض(ة) قبل استخدام عقار ريتاربين في الحالات الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أُصِبت من قبل بأي تفاعلات حساسية تجاه مضادات حيوية أخرى مثل بنيسيلين أو مضادات بيتا لاكتام الحيوية الأخرى،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من مشاكل بالكُلى (قد يحتاج طبيبك إلى ضبط جرعة هذا الدواء)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل بالكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتبع نظامًا غذائيًّا منخفض الصوديوم (الملح).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألا يُستخدم عقار ريتاربين في الأنسجة التي بها قصور في تدفق الدَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا حدثت تفاعلات حساسية (مثل الطفح الجلدي، الحكة، ضيق النفس)، فأخبر الطبيب فورًا. يجب إجراء اختبار فرط الحساسية قبل العلاج إذا كان ذلك ممكنًا. إذا حدث تفاعل حساسية، فسيوقف الطبيب علاجك ويبدأ في إعطائك العلاج الملائم إذا لزم الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نظرًا لأنه من الممكن حدوث حساسية متداخلة لدى المرضى الذين يعانون من فرط الحساسية تجاه السيفالوسبورينات، يُرجى إذًا إخبار الطبيب إذا كنت قد أُصبت من قبل بتفاعل حساسية تجاه مضادات حيوية معينة (السيفالوسبورينات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت حالتك قد شُخصت بأنك تعاني من حساسية و/أو ربو تحسسي أو حُمَّى القش، فيجب أن تخبر طبيبك بذلك. من المحتمل حدوث تفاعلات حساسية فورية شديدة حتى عند إعطاء العقار لأول مرة. واستنادًا إلى المبادئ العامة، وفي بعض الحالات على وجه الخصوص، ستظل تحت الملاحظة لمدة نصف ساعة على الأقل بعد تناول الدَّواء إذا حدث تفاعل حساسية حاد. إذا حدثت حساسية، فسيتخذ الطبيب التدابير المناسبة. يجب وقف العلاج</p><p dir="RTL">بعقار ريتاربين فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عند علاج مرض الزهري، قد يحدث تفاعل جسماني تجاه السموم البكتيرية، وقد يستمر عدة أيام (تفاعل ياريش-هِيكِسْهايمِر، انظر قسم: ٤). تتمثل الأعراض المعتادة في الحمى المفاجئة (المصحوبة في بعض الأحيان بقشعريرة) والشحوب المتبوع باحمرار الجلد والصداع وألم المفاصل والعضلات أو التَّعب. وسيبدأ طبيبك في إعطائك العلاج الملائم لكبت تفاعل ياريش-هِيكِسْهايمِر أو تخفيفه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يلزم إجراء تعديلات على الجرعة للمرضى الذين يعانون من قصور في وظائف الكُلى والمرضى الذين يعانون من قصور في وظائف الكبد (انظر قسم: ٣).</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة العلاج طويل الأمد (الذي يتجاوز ٥ أيام)، ربما يقوم طبيبك بإجراء ترتيبات لعمل فحوصات على تعداد خلايا الدَّم واختبارات وظائف الكُلى لديك. لذا يُرجى الحرص على المجيء لإجراء الفحوصات التي يقررها الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كما هو الحال مع المضادات الحيوية الأخرى، قد يؤدي أيضًا العلاج بعقار ريتاربين إلى زيادة نمو الجراثيم غير الحساسة. لذا ينبغي أن تتصل بطبيبك إذا أُصبت على سبيل المثال بعدوى فطرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يحدث إسهال خلال فترة العلاج بالمضادات الحيوية، بما في ذلك عقار ريتاربين، حتى بعد مرور عدة أسابيع من إيقاف علاجك. لذا إذا أصبح الإسهال شديدًا أو مستمرًّا أو لاحظت أن البراز يحتوي على دم أو مخاط، فاتصل بطبيبك فورًا. يجب وقف العلاج بعقار ريتاربين فورًا؛ لأنَّه قد يكون مهددًا للحياة. لا تتناول أي دواء يعمل على وقف حركة الأمعاء أو إبطائها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم يكن من الممكن استبعاد الإصابة العصبية لدى المرضى الذين يعانون من الزهري الخلقي، يجب إذًا استخدام أنواع البِنسلين التي تصل إلى مستوى أعلى في السائل النخاعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب الأخذ في الاعتبار أنَّ إزالة بوفيدون (أحد السواغات الموجودة في هذا العقار) منخفضة وذلك في حالة قصور وظائف الكُلى. ولا يمكن أن نستبعد أنه قد يحدث في حالات نادرة جدًّا تراكم للبوفيدون أو ترسيب موضعي وتكون حبيبات قد تلتبس على البعض ويظنونها أورامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أيضًا أن يوضع التأثير على الإجراءات المعملية التَّشخيصية في الاعتبار (انظر أيضًا قسم: ٤).</p><p dir="RTL">&nbsp;</p><p>تناول أدوية أخرى مع عقار ريتاربين ٦٠٠٠٠٠/١.٢/٢.٤ مليون وحدة دولية</p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب توخي الحذر عند إعطاء عقار ريتاربين في الوقت نفسه مع الأدوية التَّالية:</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروبنيسيد، دواء يُستخدم لعلاج النقرص.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثوتريكسات، دواء يُستخدم في العلاج الكيميائي. لا يوصى بتناول هذا الدَّواء بمصاحبة ميثوتريكسات.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للتجلُّط: الأدوية التي تُستَخدَم لترقيق الدَّم.</p><p dir="RTL">&nbsp;</p><p>الحمل والرضاعة الطبيعية</p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين لذلك، فاستشيري طبيبكِ أو الصيدلي الخاص بكِ قبل تناوُل هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">يمكن استخدام عقار ريتاربين أثناء فترة الحمل بعد أن يقوم الطبيب الذي يصف العقار بإجراء التشخيص الملائم وينظر بشكل متأنٍ في فوائد العقار مقابل مخاطره.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">تفرز كميات بسيطة من المادة الفعَّالة التي تسمى بنزل بنسلين في حليب ثدي الأم.</p><p dir="RTL">على الرغم من أنه لم يتم رصد أي آثار جانبية حتى الآن بين الرضع الصغار الذين يرضعون حليب ثدي الأم، إلا إنه لا بد من الوضع في الاعتبار احتمالية حدوث تحْسيس أو تداخل مع النبيت الجرثومي المعوي. في حالة إصابة الطفل بإسهال أو مرض المبيضات أو طفح جلدي، استشر الطبيب فورًا؛ لأنَّ هذه الاضطرابات التي تصيب الطفل قد تكون ناجمة عن العلاج بعقار ريتاربين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة للرضع الصغار الذين يتغذون أيضًا على طعام الأطفال، فإنه يجب على أمهاتهم استخراج لبن حليب أثدائهن والتَّخلص منه. ويمكنهن البدء في إرضاع أطفالهن طبيعيًّا مرة أخرى بعد مرور ٢٤ ساعة من انتهاء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>القيادة واستخدام الآلات</p><p dir="RTL">قد يُضعف هذا الدَّواء الاستجابة والقدرة على القيادة.</p><p dir="RTL">نظرًا لأنَّ العلاج بعقار ريتاربين قد ينجم عنه آثار جانبية خطيرة (مثل الصدمة التَّأقية المصحوبة بهبوط والتَّفاعُلات التَّأَقانِيّة، انظر قسم: ٤)، يمكن أن يكون للعلاج بعقار ريتاربين تأثير كبير على القدرة على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p>يحتوي عقار ريتاربين ٦٠٠٠٠٠/١.٢/٢.٤ مليون وحدة دولية على دهون فوسفورية من فول الصويا</p><p dir="RTL">لذا ينبغي ألا تستخدم هذا المنتج الدوائي إذا كنت تعاني من حساسية للفول السوداني أو الصويا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي</strong> <strong>عقار ريتاربين ٦٠٠٠٠٠ وحدة دولية</strong><strong>/</strong><strong>١</strong><strong>.</strong><strong>٢ مليون وحدة دولية على</strong> <strong>أقل من ١ مللي مول صوديوم </strong><strong>(</strong><strong>٢٣ مجم</strong><strong>) </strong><strong>لكل جرعة،</strong> مما يعني أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي وبالتَّالي يمكن للمرضى الذين يتبعون نظامًا غذائيًّا منضبط الصوديوم استخدامه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي</strong> <strong>عقار ريتاربين ٢</strong><strong>.</strong><strong>٤ مليون وحدة دولية على</strong> <strong>٤٠</strong><strong>.</strong><strong>١ مجم صوديوم </strong>(المكون الرئيسي لملح المائدة/الطعام)<strong> لكل جرعة</strong>. وهذا يُعادل ٢٪ من الحد الأقصى اليومي للكمية الغذائية من الصوديوم المُوصى بتناولها للبالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>من حيث المبدأ، فإنَّ عقار ريتاربين يتم إعطاؤه بواسطة ممارس صحي</strong><strong>. </strong><strong>الجرعة الموصى بها هي</strong><strong>:</strong></p><p dir="RTL"><u>العلاج العام</u><u>:</u></p><p dir="RTL">البالغون والمراهقون:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ١.٢ مليون وحدة دولية مرة واحدة في الأسبوع الأطفال الذين تزيد أوزانهم عن ٣٠ كجم: ١.٢ مليون وحدة دولية مرة واحدة في الأسبوع الأطفال الذين تقل أوزانهم عن ٣٠ كجم: ٦٠٠٠٠٠ وحدة دولية مرة واحدة في الأسبوع مدة العلاج:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة واحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>علاج مرض الزهري</u><u>:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; المرحلة الرئيسية والثانوية</p><p dir="RTL">البالغون والمراهقون:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ١ &times; ٢.٤ مليون وحدة دولية</p><p dir="RTL">الأطفال:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٥٠٠٠٠ وحدة دولية/ كجم وزن الجسم، مع مراعاة ألا تزيد عن ٢.٤ مليون وحدة دولية</p><p dir="RTL">(إذا عادت الأعراض السريرية أو ظلت النتائج المعملية موجبة للغاية، فلا بد من تكرار العلاج).</p><p dir="RTL">مدة العلاج:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة واحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مرض الزهري في المرحلة المتأخرة (مرض الزهري المصلي الكامن)</p><p dir="RTL">البالغون والمراهقون:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٢.٤ مليون وحدة دولية في الأسبوع.</p><p dir="RTL">الأطفال:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٥٠٠٠٠ وحدة دولية/كجم وزن الجسم، مع مراعاة ألا تزيد عن ٢.٤ مليون وحدة دولية.</p><p dir="RTL">مدة العلاج:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثلاث أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; علاج مرض الزهري الخلقي: بدون الإصابة العصبية</p><p dir="RTL">حديثو الولادة والرضع:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ١ &times; ٥٠٠٠٠ وحدة دولية/ كجم وزن الجسم.</p><p dir="RTL">مدة العلاج:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>علاج الأمراض الجلدية المعدية المدارية </u><u>(</u><u>المرض العليقي، مرض بنتا</u><u>): </u></p><p dir="RTL">البالغون والمراهقون:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ١ &times; ١.٢ مليون وحدة دولية</p><p dir="RTL">الأطفال الذين تزيد أوزانهم عن ٣٠ كجم: ١ &times; ١.٢ مليون وحدة دولية</p><p dir="RTL">الأطفال الذين تقل أوزانهم عن ٣٠ كجم: ١ &times; ٦٠٠٠٠٠ وحدة دولية</p><p dir="RTL">مدة العلاج:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة واحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الوقاية من الإصابة بالحمى الروماتيزمية والتهاب كبيبات الكُلى التَّالِي للعِقْدِيَّات والحُمْرَة</u><u>: </u>البالغون والمراهقون:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ١ &times; ١.٢ مليون وحدة دولية كل ٣-٤ أسابيع</p><p dir="RTL">الأطفال الذين تزيد أوزانهم عن ٣٠ كجم:&nbsp;&nbsp; ١ &times; ١.٢ مليون وحدة دولية كل ٣-٤ أسابيع</p><p dir="RTL">الأطفال الذين تقل أوزانهم عن ٣٠ كجم: ١ &times; ٦٠٠٠٠٠ وحدة دولية كل ٣-٤ أسابيع مدة العلاج:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; &zwnj;أ)&nbsp;&nbsp;&nbsp; بدون إصابة القلب: ٥ سنوات على الأقل، أو حتى بلوغ ٢١ سنة</p><p dir="RTL">&nbsp;&nbsp;&nbsp; &zwnj;ب)&nbsp;&nbsp; إصابة القلب المؤقتة: ١٠ سنوات على الأقل، أو حتى بلوغ ٢١ سنة</p><p dir="RTL">&nbsp;&nbsp;&nbsp; &zwnj;ج)&nbsp;&nbsp; إصابة القلب الدائمة: ١٠ سنوات على الأقل، أو حتى بلوغ ٤٠ سنة؛ يكون العلاج مدى الحياة ضروريًّا في بعض الأحيان.</p><p dir="RTL">&nbsp;</p><p>المجموعات الخاصَّة من المرضى (الذين يعانون من قصور وظائف الكبد أو قصور وظائف الكُلى)</p><p dir="RTL">سيحدد طبيبك الجرعة والفاصل الزمني بين تناول الجرعات. إذا كانت لديك أية أسئلة بخصوص الجرعة، فيُرجى الاتصال بطبيبك.</p><p dir="RTL">&nbsp;</p><p>طريقة التَّناول</p><p dir="RTL">ينبغي حقن المستحضر في العضل فقط (الإعطاء في العضل).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب <u>عدم</u> الحقن في الأنسجة التي بها قصور في تدفق الدَّم.</p><p dir="RTL">يجب تغيير موضع الحَقن في حالة الإعطاء المتكرر في العضل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تحدث تفاعلات موضعية شديدة أثناء الإعطاء في العضل، خاصةً لدى الأطفال الصغار. ولهذا السبب، يمكن استخدام علاجات أخرى مثل تركيبة بِنسلين مختلفة إذا كان ذلك ممكنًا.</p><p dir="RTL">&nbsp;</p><p>في حالة إعطائك كمية أكثر مما يجب من عقار ريتاربين</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يمكن أن تتسبب الجرعات العالية للغاية من البِنسلينات في حدوث استثارة عصبية عضلية أو نوبات صرعية الشكل. إذا كان هناك اشتباه بإعطاء جرعة زائدة، فاستشر طبيبًا فورًا.</p><p dir="RTL">&nbsp;</p><p>في حالة إغفال أن يتم إعطاؤك عقار ريتاربين</p><p dir="RTL">إذا اعتقدت أنك لم تُعط جرعة ما، فأخبر طبيبك بذلك فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي أو الممرض(ة) الخاصين بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع. شائعة جدًّا: قد تُؤثر على أكثر من شخص واحد من بين كل 10&nbsp;أشخاص</p><p dir="RTL">شائعة: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص</p><p dir="RTL">غير شائعة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تُؤثر على شخص واحد من كل 100 شخص نادرة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تُؤثر على شخص واحد من كل 1000 شخص نادرة جدًّا:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تُؤثر على شخص واحد من كل 10000 شخص</p><p dir="RTL">غير معروفة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة</p><p dir="RTL">&nbsp;</p><p><strong>العدوى والاحتشار (عدوى الطفيليات)</strong></p><p dir="RTL">شائعة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الفطرية (داء المبيضات)</p><p dir="RTL">&nbsp;</p><p><strong>اضطرابات الدَّم والجهاز الليمفاوي</strong></p><p dir="RTL">نادرة جدًّا:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات دم معينة (تسمى فقر الدَّم الانحلالي، نقص كرَيَّاتِ الدَّم البيْضاء، نقص الصَّفائح الدَّموية، ندرة خلايا المحببات).</p><p dir="RTL">&nbsp;</p><p><strong>اضطرابات الجهاز المناعي</strong></p><p dir="RTL">نادرة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية: طفح القراص (أرتكاريا)، وَذَمَة وِعائِيَّة (تورُّم)، تفاعلات جلدية (احمرار متعدد الأشكال، التهاب الجلد التقشري)، حمى، ألم بالمفاصل، صدمة تأقية مصحوبة بهبوط وتَفاعُلات تَأَقانِيّة (الربو، نزيف من الجلد يعرف باسم الفرفرية، شكاوى الجهاز الهضمي).</p><p dir="RTL">غير معروفة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء المصل. عند علاج مرض الزهري، قد يحدث تفاعل ياريش-هِيكِسْهايمِر نتيجة انحلال الجراثيم، الذي يتسم بحدوث حمى وقشعريرة وأعراض عامة وبؤرية. بالنسبة للمرضى المصابين بفطر جلدي، فقد تحدث لديهم تفاعلات حساسية إضافية.</p><p dir="RTL"><em>&nbsp;&nbsp;</em></p><p><strong>اضطرابات الجهاز الهضمي</strong></p><p dir="RTL">شائعة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إِسهال، غثيان.</p><p dir="RTL">غير شائعة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بطانة الفم (الْتِهاب الفَم) والشعور بحرقة في اللسان (التهاب اللسان) وقيء غير معروفة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الْتِهاب القولونِ الغِشائِيُّ الكاذِب (انظر أيضًا قسم: ٢).</p><p dir="RTL">&nbsp;</p><p><strong>اضطرابات الكبد والقنوات المرارية</strong></p><p dir="RTL">غير معروفة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد، قصور في تدفق العصارة الصفراوية (ركود صفراوي).</p><p dir="RTL">&nbsp;</p><p><strong>اضطرابات الكُلى والمسالك البولية</strong></p><p dir="RTL">نادرة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض بالكُلى (اعتلال الكُلى)، التهاب الكُلى (التهاب الكلية الخلالي).</p><p dir="RTL">&nbsp;</p><p><strong>اضطرابات عامة وتلك المتعلقة بموضع التَّناول</strong></p><p dir="RTL">غير معروفة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بموضع الحقن، تهيج في موضع الحقن.</p><p dir="RTL">&nbsp;</p><p><strong>الفحوصات</strong></p><p dir="RTL">شائعة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في فحوصات واختبارات معينة، مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الحصول على نتيجة إيجابية في اختبار كومبس المباشر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الحصول على نتائج إيجابية كاذبة في الاختبارات التي تستخدم للتحقق من وجود بروتينات في البول، باستخدام طرق الترسيب (طريقة فولن سيكالتيو لاوري، طريقة بايوريت).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الحصول على نتائج إيجابية كاذبة في الاختبارات التي تستخدم للتَّحقق من وجود بروتينات في البول (طريقة نينهيدرين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; وجود مشابه كاذب لثنائي الألبومين في الدَّم عند استخدام طرق الرحلان الكهربائي للتَّحقق من وجود الألبومين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الحصول على نتائج إيجابية كاذبة في الاختبارات غير الإنزيمية التي تستخدم للتحقق من وجود الجلوكوز في البول واليوروبيلينوجين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; زيادة المستويات عند التحقق من وجود كيتوستيرويدات - ١٧ في البول (باستخدام تفاعل زيمرمان) (انظر قسم: ٢).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>نظرًا لاحتواء الدَّواء على بوفيدون، فلا يمكن أن نستبعد أنه قد يحدث في حالات نادرة جدًّا تراكم للبوفيدون في الجُمْلَة الشَّبَكِيَّة البِطانِيَّة أو ترسيبات موضعية وتكون حبيبات بالجسم قد تلتبس على البعض ويظنونها أورامًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على الملصق والكرتون والحاوية بعد كلمة &quot;EXP&quot; يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;&nbsp;يخزن في درجة حرارة أقل من 25 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أية أدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعد تستخدمها. ستُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي بنزاثين بنزل بنيسيللين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي عقار ريتاربين ٦٠٠٠٠٠/١.٢ /٢.٤ مليون وحدة دولية مسحوق ومُذيب لإعداد معلق للحقن على ٦٠٠٠٠٠/١.٢ مليون/٢.٤ مليون وحدة دولية بنزاثين بنزل بنيسيللين (دهون فوسفورية من فول الصويا).</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي: بوفيدون، سيميثيكون، سترات الصوديوم، مانيتول (E421). وتحتوي الزجاجة الواحدة من المذيب على ٥ مللي لتر من ماء الحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مسحوق ومُذيب لإعداد معلق للحقن لونه أبيض يميل إلى اللون الكريمي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">زجاجة شفافة سعة ٥/٥/١٥ مللي لتر من النوع الثالث (وفقًا لهيئة دستور الأدوية الأوروبية) مغلقة بسدادة مطاطية من البوتيل المهلجن وغطاء ألومنيوم.</p><p dir="RTL">المذيب: زجاجة بلاستيكية مصنوعة من البولي إيثيلين وتبلغ سعتها الاسمية ٥مللي لتر.</p><p dir="RTL">&nbsp;عبوة بها 1 &Iacute; مسحوق ومُذيب لإعداد معلق للحقن.</p><p dir="RTL">عبوة بها 1 &Iacute; أو 100 &Iacute;مسحوق ومُذيب لإعداد معلق للحقن.</p><p dir="RTL">عبوة بها 1 &Iacute; &nbsp;أو 50 &Iacute; &nbsp;مسحوق ومُذيب لإعداد معلق للحقن.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ساندوز المحدودة</p><p dir="RTL">6250&nbsp;كوندل</p><p>النمسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            2020/07
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Retarpen 600,000 IU powder and solvent for suspension for injection
Retarpen 1.2 MIU powder and solvent for suspension for injection
Retarpen 2.4 MIU powder and solvent for suspension for injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial Retarpen 600,000 IU powder and solvent for suspension for injection contains: 600,000 IU benzathine benzylpenicillin.

Excipient(s) with known effect
Each vial contains traces phospholipids from the soya beans.

One vial {Retarpen 1.2 MIU powder and solvent for suspension for injection} contains: 1,200,000 IU benzathine benzylpenicillin.

Excipient(s) with known effect
Each vial contains traces phospholipids from the soya beans.

One vial {Retarpen 2.4 MIU powder and solvent for suspension for injection} contains: 2,400,000 IU benzathine benzylpenicillin.

Excipient(s) with known effect
Each vial contains traces phospholipids from the soya beans. Contains 1.745 mmol (40.1 mg) sodium per dose.


For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for suspension for injection. 
White to cream-coloured powder.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Retarpen is indicated in adults, adolescents, children and neonates for the treatment&nbsp; and&nbsp; prophylaxis of the following infections caused by pathogens sensitive to penicillin (see section 5.1):</p><p>&nbsp;</p><p>For the treatment of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erysipelas</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; syphilis: early syphilis (primary and secondary)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; latent syphilis (except for neurosyphilis and presence of pathological CSF findings)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yaws</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pinta</p><p>&nbsp;</p><p>For the prophylaxis of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rheumatic fever (chorea, rheumatic carditis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; poststreptococcal glomerulonephritis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erysipelas</p><p>&nbsp;</p><p>When using Retarpen, consideration should be given to the general guidelines on the appropriate&nbsp; use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The dosing recommendations depend on the severity and the type of infection, the age and the hepato- renal function of patients. International guidelines should be considered in addition to national or&nbsp;&nbsp; local guidance for some specific indications (eg syphilis, prophylaxis of rheumatic fever).</p><p>&nbsp;</p><p>Dosage and duration of treatment</p><p><strong>&nbsp;</strong></p><p><em>General therapy:</em></p><p>Adults and adolescents:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.2 mio IU once weekly Children &gt; 30 kg body weight: 1.2 mio IU once weekly Children &lt; 30 kg body weight: 600,000 IU once weekly Duration of treatment:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; single dose</p><p>(In streptococcal diseases, a 10-day minimum course of treatment should be observed to avoid secondary&nbsp; diseases.&nbsp; This&nbsp; is&nbsp; generally ensured&nbsp; with&nbsp; a&nbsp; single&nbsp; injection of {Retarpen} 600,000&nbsp;&nbsp;&nbsp; IU,</p><p>{Retarpen} 1.2 mio IU or {Retarpen} 2.4 mio IU.)</p><p>&nbsp;</p><p><em>Treatment of syphilis:</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Primary and secondary stage</em></p><p>Adults and adolescents:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 x 2.4 mio IU</p><p>Children:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50,000 IU/kg body weight, however not more than 2.4 mio IU</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>(If clinical symptoms recur or laboratory findings remain strongly positive, treatment should be repeated.)</p><p>Duration of treatment:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; single dose</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Late-stage syphilis (latent seropositive syphilis)</em></p><p>Adults and adolescents:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.4 mio IU once weekly</p><p>Children:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50,000 IU/kg body weight, however not more than 2.4 mio IU</p><p>Duration of treatment:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3 weeks</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Treatment of congenital syphilis: without neurological involvement</em></p><p>Neonates and infants:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 x 50,000 IU/kg body weight Duration of treatment:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; single dose</p><p>&nbsp;</p><p><em>Treatment of yaws, pinta:</em></p><p>Adults and adolescents:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 x 1.2 mio IU Children &gt; 30 kg body weight: 1 x 1.2 mio IU Children &lt; 30 kg body weight: 1 x 600,000 IU Duration of treatment:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; single dose</p><p>&nbsp;</p><p><em>Prophylaxis of rheumatic fever, poststreptococcal glomerulonephritis and erysipelas:</em></p><p>Adults and adolescents:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 x 1.2 mio IU every 3-4 weeks Children &gt; 30 kg body weight: 1 x 1.2 mio IU every 3-4 weeks Children &lt; 30 kg body weight: 1 x 600,000 IU every 3-4 weeks Duration of treatment:</p><p>a)&nbsp; without cardiac involvement: at least 5 years, or up to 21 years of age</p><p>b)&nbsp; transient cardiac involvement: at least 10 years, or up to 21 years of age</p><p>c)&nbsp; persistent cardiac involvement: at least 10 years or up to 40 years of age; life-long prophylaxis is sometimes necessary.</p><p>&nbsp;</p><p><em><u>Special patient groups</u></em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image1.png" o:spid="_x0000_s1061" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:186.85pt;
 margin-top:57.35pt;width:.5pt;height:65.3pt;z-index:-251664896;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="1" height="87" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:shape id="_x0000_s1060"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:294.95pt;margin-top:57.35pt;width:.5pt;height:65.3pt;z-index:-251663872;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="1" height="87" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.gif" /><!--[if gte vml 1]><v:shape id="_x0000_s1059"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:403.1pt;margin-top:57.35pt;width:.5pt;height:65.3pt;z-index:-251662848;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="1" height="87" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.gif" /><em><u>Patients with impaired renal function</u></em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p>{Retarpen} dosage for adults, adolescents and children based on creatinine clearance</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine clearance in ml/min</p></td><td style="vertical-align:top"><p>100-60</p></td><td style="vertical-align:top"><p>50-10</p></td><td style="vertical-align:top"><p>&lt;10</p></td></tr><tr><td style="vertical-align:top"><p>Serum creatinine in mg%</p></td><td style="vertical-align:top"><p>0.8-1.5</p></td><td style="vertical-align:top"><p>1.5-8.0</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td style="vertical-align:top"><p>Proportion&nbsp;&nbsp;&nbsp;&nbsp; of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the</p></td><td style="vertical-align:top"><p>100%</p></td><td style="vertical-align:top"><p>75%</p></td><td style="vertical-align:top"><p>20-50%</p></td></tr></tbody></table><p>&nbsp;</p><p><em>&nbsp;</em></p><p><!--[if gte vml 1]><o:wrapblock><v:group id="_x0000_s1026"
  style='position:absolute;margin-left:78.85pt;margin-top:15.75pt;width:460.2pt;
  height:54pt;z-index:251656704;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page'
  coordorigin="1577,315" coordsize="9204,1080">
  <v:line id="_x0000_s1027" style='position:absolute' from="1586,327" to="3739,327"
   strokeweight=".6pt"/>
  <v:line id="_x0000_s1028" style='position:absolute' from="3737,327" to="3749,327"
   strokeweight=".6pt"/>
  <v:line id="_x0000_s1029" style='position:absolute' from="3746,327" to="5902,327"
   strokeweight=".6pt"/>
  <v:line id="_x0000_s1030" style='position:absolute' from="5899,327" to="5911,327"
   strokeweight=".6pt"/>
  <v:line id="_x0000_s1031" style='position:absolute' from="5909,327" to="8064,327"
   strokeweight=".6pt"/>
  <v:line id="_x0000_s1032" style='position:absolute' from="8062,327" to="8074,327"
   strokeweight=".6pt"/>
  <v:line id="_x0000_s1033" style='position:absolute' from="8071,327" to="10771,327"
   strokeweight=".6pt"/>
  <v:line id="_x0000_s1034" style='position:absolute' from="1586,855" to="3739,855"
   strokeweight=".6pt"/>
  <v:line id="_x0000_s1035" style='position:absolute' from="3737,855" to="3749,855"
   strokeweight=".6pt"/>
  <v:line id="_x0000_s1036" style='position:absolute' from="3746,855" to="5902,855"
   strokeweight=".6pt"/>
  <v:line id="_x0000_s1037" style='position:absolute' from="5899,855" to="5911,855"
   strokeweight=".6pt"/>
  <v:line id="_x0000_s1038" style='position:absolute' from="5909,855" to="8064,855"
   strokeweight=".6pt"/>
  <v:line id="_x0000_s1039" style='position:absolute' from="8062,855" to="8074,855"
   strokeweight=".6pt"/>
  <v:line id="_x0000_s1040" style='position:absolute' from="8071,855" to="10771,855"
   strokeweight=".6pt"/>
  <v:line id="_x0000_s1041" style='position:absolute' from="1583,321" to="1583,1389"
   strokeweight=".6pt"/>
  <v:line id="_x0000_s1042" style='position:absolute' from="1586,1383" to="3739,1383"
   strokeweight=".6pt"/>
  <v:shape id="_x0000_s1043" type="#_x0000_t75" style='position:absolute;
   left:3737;top:331;width:10;height:1046'>
   <v:imagedata src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.png"
    o:title=""/>
  </v:shape><v:line id="_x0000_s1044" style='position:absolute' from="3737,1383"
   to="3749,1383" strokeweight=".6pt"/>
  <v:line id="_x0000_s1045" style='position:absolute' from="3746,1383" to="5902,1383"
   strokeweight=".6pt"/>
  <v:shape id="_x0000_s1046" type="#_x0000_t75" style='position:absolute;
   left:5899;top:331;width:10;height:1046'>
   <v:imagedata src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.png"
    o:title=""/>
  </v:shape><v:line id="_x0000_s1047" style='position:absolute' from="5899,1383"
   to="5911,1383" strokeweight=".6pt"/>
  <v:line id="_x0000_s1048" style='position:absolute' from="5909,1383" to="8064,1383"
   strokeweight=".6pt"/>
  <v:shape id="_x0000_s1049" type="#_x0000_t75" style='position:absolute;
   left:8062;top:331;width:10;height:1046'>
   <v:imagedata src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.png"
    o:title=""/>
  </v:shape><v:line id="_x0000_s1050" style='position:absolute' from="8062,1383"
   to="8074,1383" strokeweight=".6pt"/>
  <v:line id="_x0000_s1051" style='position:absolute' from="8071,1383" to="10771,1383"
   strokeweight=".6pt"/>
  <v:line id="_x0000_s1052" style='position:absolute' from="10775,321" to="10775,1389"
   strokeweight=".6pt"/>
  <v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
   <v:stroke joinstyle="miter"/>
   <v:path gradientshapeok="t" o:connecttype="rect"/>
  </v:shapetype><v:shape id="_x0000_s1053" type="#_x0000_t202" style='position:absolute;
   left:1702;top:340;width:1940;height:504' filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1053' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='line-height:12.2pt;mso-line-height-rule:exactly'>normal<span
      style='mso-spacerun:yes'>  </span>daily<span style='mso-spacerun:yes'> 
      </span>dose of<o:p></o:p></p>
      <p class=MsoNormal style='margin-top:.3pt'>{Retarpen}<o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1054" type="#_x0000_t202" style='position:absolute;
   left:8530;top:340;width:1797;height:245' filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1054' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='line-height:12.2pt;mso-line-height-rule:exactly'>(1-3
      mio IU/d max.)<o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1055" type="#_x0000_t202" style='position:absolute;
   left:1702;top:998;width:1412;height:245' filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1055' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='line-height:12.2pt;mso-line-height-rule:exactly'>Dosage
      interval<o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1056" type="#_x0000_t202" style='position:absolute;
   left:4183;top:868;width:1300;height:504' filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1056' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='margin-right:.45pt;text-indent:8.85pt;
      line-height:101%'>in 1 single administration<o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1057" type="#_x0000_t202" style='position:absolute;
   left:6343;top:868;width:1300;height:504' filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1057' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='margin-right:.45pt;text-indent:9.0pt;
      line-height:101%'>in 1 single administration<o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1058" type="#_x0000_t202" style='position:absolute;
   left:8736;top:868;width:1386;height:504' filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1058' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='margin-right:.45pt;text-indent:6.6pt;
      line-height:101%'>in 2-3 single administrations<o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="615" height="73" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em><u>Haemodialysis patients</u></em></p><p>Benzathin-Benzylpenicillin can be removed by hemodialysis. There are no data available on the influence of dialysis on the plasma levels of benzyl penicillin. The decision to treat patients on&nbsp; dialysis with {Retarpen} needs therefore to be taken on a case by case basis.</p><p>&nbsp;</p><p><em><u>Patients with impaired hepatic function</u></em></p><p>In very severe cases of impaired hepatic and renal function, there may be a delay in the degradation and excretion of penicillins.</p><p>&nbsp;</p><p>Method of administration</p><p><strong>&nbsp;</strong></p><p>The preparation is <u>strictly for intramuscular </u>injection (see section 4.4).</p><p>&nbsp;</p><p>The injection must not be administered into tissue with reduced perfusion (see section 4.4).</p><p>&nbsp;</p><p>{Retarpen} should be administered by deep intramuscular injection into the upper, outer quadrant of the gluteus maximus or Hochstetter&#39;s ventrogluteal field, with the needle pointing towards the iliac crest or according to von Hochstetter&#39;s method. The puncture should be as vertical to the skin surface as possible and the injection as far away from major vessels as possible. In all events, aspiration must be performed prior to the injection. If aspiration of blood or pain occurs during the injection, it must&nbsp; be discontinued.</p><p>&nbsp;</p><p>In children, the mid-lateral thigh muscles (quadriceps femoris) are recommended as an injection site. The deltoid muscle is only suitable if it is well formed; in this case, attention must be paid to the&nbsp; radial nerve.</p><p>In infants and young children, the peripheral area of the upper outer quadrant of the gluteal region should be used as the area for injection only in exceptional cases (e.g. widespread burns), in order to avoid sciatic nerve lesions.</p><p>&nbsp;</p><p>For depot preparations, a total volume of 5 ml per injection site is stated as the tolerance limit. Thus, no more than 5 ml of the ready-to-inject suspension should be administered at any one time into one site.</p><p>&nbsp;</p><p>The injection should be given as slowly as possible and only with the application of low pressure. &ldquo;Rubbing&rdquo; after the injection should be avoided.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Severe local reactions may occur during intramuscular administration, especially in young children. If possible, taking notably into account the therapeutic indications and schedule regimens and weighing the benefit-risk ratio, alternative treatments such as intravenous therapy with a suitable penicillin product should be considered (see also section 4.4).</p><p>&nbsp;</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Hypersensitivity to the active substance benzathine benzylpenicillin, to any of the penicillins, soya, peanut or to any of the excipients listed in section 6.1.
History of a severe immediate hypersensitivity reaction (eg anaphylaxis) to another beta-lactam agent (eg cephalosporin, carbapenem or monobactam).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Retarpen should not be used in tissues with reduced perfusion.</p><p>Before initiating therapy with Retarpen, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other beta-lactam agents (see sections 4.3 and 4.8).</p><p>Serious and occasionally fatal hypersentivity reactions have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and in atopic individuals. If an allergic reaction occurs, Retarpen must be&nbsp; discontinued and appropriate therapy instituted.</p><p>&nbsp;</p><p>&nbsp;</p><p>Prior to treatment, a hypersensitivity test should be performed if possible. The patient should be made aware of the possible occurrence of allergic symptoms and of the need to report them.</p><p>&nbsp;</p><p>Caution should be exercised in patients with the following conditions:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic diathesis or bronchial asthma (there is an increased risk of a hypersensitivity&nbsp; reaction):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in renal insufficiency (for dose adjustment, see section 4.2);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in impaired hepatic function (see section 4.2);</p><p>&nbsp;</p><p>Based on a general principle, in particular in some exposed patients, a medical observation should if possible be ensured for at last half an hour after the administration of this antibiotic, as severe immediate allergic reactions may occur even after the first administration.</p><p>&nbsp;</p><p>When treating syphilis, a Jarisch-Herxheimer reaction may occur as a result of the bactericidal action of penicillin on pathogens. 2 to 12 hours after administration headaches, fever, sweating, shivering, myalgia, arthralgia, nausea, tachycardia, increased blood pressure followed by hypotension&nbsp; may occur. These symptoms resolve after 10 to 12 hours. Patients should be informed that this is a usual, transient sequela of antibiotic therapy. Appropriate therapy should be instituted to suppress or&nbsp; attenuate a Jarisch-Herxheimer reaction (see section 4.8).</p><p>&nbsp;</p><p>&nbsp;</p><p>In long-term treatment (more than 5 days), blood count monitoring and renal function tests are recommended.</p><p>&nbsp;</p><p>Vigilance is required for overgrowth of resistant germs. At the onset of secondary infections, appropriate measures should be taken.</p><p>&nbsp;</p><p>In the event of severe and persistent diarrhoea, antibiotic-associated pseudomembranous colitis (bloody/mucoid, watery diarrhoea, dull, diffuse-to-colicky abdominal pain, fever, occasionally tenesmus) should be considered, which can be life-threatening. In these cases, {Retarpen} should therefore be discontinued immediately and therapy instituted based on pathogen detection results. Antiperistaltic agents are contraindicated.</p><p>&nbsp;</p><p>&nbsp;</p><p>If neurological involvement cannot be excluded in patients with congenital syphilis, forms of&nbsp; penicillin that reach a higher level in cerebrospinal fluid should be used.</p><p>&nbsp;</p><p>In diseases such as severe pneumonia, empyema, sepsis, meningitis or peritonitis, which require&nbsp; higher serum penicillin levels, alternative treatment such as the water-soluble alkali salt of benzyl penicillin should be considered.</p><p>&nbsp;</p><p>Notes on administering Retarpen</p><p><strong><em>&nbsp;</em></strong></p><p>Painful induration may occur in the event of accidental subcutaneous administration. Ice packs help in such cases.</p><p>&nbsp;</p><p>In the event of inadvertent intravascular injection, Hoign&eacute;&#39;s syndrome may occur (symptoms of shock with mortal fear, confusion, hallucinations, possibly cyanosis, tachycardia and motor disorders, although no circulatory collapse), caused by microemboli of the suspension. The symptoms regress within an hour. If progression is severe, parenteral administration of sedatives is indicated.</p><p>&nbsp;</p><p>In the event of inadvertent intra-arterial injection, particularly in children, serious complications may occur, such as vascular occlusion, thrombosis and gangrene. Initial signs are pale patches in the skin</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>area of the gluteal region. As a result of high injection pressure, retrograde entry of the injected liquid into the common iliac artery, aorta or spinal arteries may occur.</p><p>&nbsp;</p><p>Repeated injections into a limited area of the muscle tissue, which are associated with long term therapy with depot-penicillins (e.g. in the treatment of syphilis) may induce tissue damage and increased local vascularization. Subsequent injections increase the possibility of penetration of injection substance into the blood, either by direct injection into a blood vessel or caused by the injection pressure itself, or by &ldquo;rubbing&rdquo; of the depot. During long term therapy it is therefore recommended to administer each injection on large distance from the precedent injection.</p><p>&nbsp;</p><p>&nbsp;</p><p>Decreased elimination of povidone should be considered in case of impairment of renal function. Due to the amount of povidone, it cannot be excluded that frequent or long term administration can lead in very rare cases to an accumulation of povidone in the reticulo-endothelial system (RES), or to a local deposition and formation of granulomas which may be confused with tumors.</p><p>&nbsp;</p><p><em>Effect on diagnostic laboratory procedures:</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A positive direct Coombs&rsquo; test often develops (&ge; 1% to &lt; 10%) in patients receiving 10 million&nbsp; IU (equivalent to 6 g) benzylpenicillin or more per day. After discontinuation of the penicillin,&nbsp; the direct antiglobulin test may still remain positive for 6 to 8 weeks (see section 4.8).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Determination of urinary protein using precipitation techniques (sulphosalicylic acid, trichloroacetic acid), the Folin-Ciocalteu-Lowry method or the biuret method may lead to false- positive results. Urinary protein should therefore be determined by other methods.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary amino acid determination using the ninhydrin method may likewise lead to false-positive results.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Penicillins bind to albumin. In electrophoresis methods to determine albumin, pseudobisalbuminaemia may therefore be simulated.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During therapy with Retarpen, non-enzymatic urinary glucose detection and urobilinogen detection may prove false-positive.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When determining 17-ketosteroids (using the Zimmermann reaction) in the urine, increased values may occur during therapy with Retarpen.</p><p>&nbsp;</p><p>Retarpen 600,000/1.2/2.4 MIU &nbsp;contains phospholipids from the soja bean, caution is warranted on the risk of allergic reactions.</p><p>&nbsp;</p><p>Retarpen 600,000 IU/1.2 MIU contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p><p>Retarpen 2.4 MIU powder and solvent for suspension for injection contains 40.1 mg sodium per dose, equivalent to 2.0% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Concomitant administration of benzathine benzylpenicillin is not recommended with:</u></p><p>&nbsp;</p><p>Based on the general principle not to combine bactericidal and bacteriostatic antibiotics, Retarpen should not be combined with bacteriostatic antibiotics.</p><p>&nbsp;</p><p><u>Caution should be exercised when co-administering the following:</u></p><p>&nbsp;</p><p><em>Probenecid: </em>the administration of probenecid leads to inhibition of the tubular secretion of benzylpenicillin, resulting in an increase in the serum concentration and prolongation of the elimination half-life. Furthermore probenicid inhibits the penicillin transport from the cerebrospinal fluid, so that the concomitant administration of probenecid reduces the penetration of benzyl&nbsp; penicillin into brain tissue even further.</p><p>&nbsp;</p><p><em>Methotrexate: </em>when taken at the same time as benzathine benzylpenicillin, the excretion of methotrexate is reduced. This can lead to increased methotrexate toxicity. The combination with methotrexate is not recommended.</p><p>&nbsp;</p><p><em>Anticoagulants</em>: Concomitant use with oral anticoagulants may increase the anti-vitamin K effect and the risk of bleeding. It is recommended that the International Normalised Ratio (INR) is monitored frequently and the posology of the anti-vitamin K drug adjusted accordingly, both during and after treatment with Retarpen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Benzathine benzylpenicillin crosses the placenta. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Retarpen can be used during pregnancy when appropriately indicated and with due consideration of the benefits and risks.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Benzathine benzylpenicillin is excreted in human milk in small amounts. The concentration in maternal milk may reach 2 to 15% of the mother&rsquo;s serum concentrations.</p><p>Although no undesirable effects in infants fed on breast milk have been reported to date,&nbsp; consideration must nevertheless be given to the possibility of sensitisation or interference with the intestinal flora. Breast-feeding should be stopped in the case of occurrence of diarrhoea, candidosis or rash in the child.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>In infants also being fed on baby food, mothers should express and discard breast milk during benzathine benzylpenicillin treatment. Breast-feeding can be resumed upon cessation of treatment 24 hours later.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No fertility studies have been conducted in humans. Reproductive studies on mice, rats and rabbits have not revealed any negative effects on fertility. No long-term fertility studies on laboratory animals are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to the occurrence of possible serious undesirable effects (e.g. anaphylactic shock with collapse&nbsp; and anaphylactoid reactions, see also section 4.8), Retarpen can have a major influence on the&nbsp; ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The undesirable effects are arranged according to body system and their frequency is categorised as follows:</p><p>&nbsp;</p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge; 1/10</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge; 1/100, &lt; 1/10</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge; 1/1,000, &lt; 1/100</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge; 1/10,000, &lt; 1/1,000</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1/10,000</p><p>Not known&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (cannot be estimated from the available data)</p><p>&nbsp;</p><p>Infections and infestations</p><p><em>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>candidiasis</p><p>&nbsp;</p><p>Blood and lymphatic system disorders</p><p><em>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>haemolytic anaemia, leukopenia, thrombocytopenia, agranulocytosis.</p><p>&nbsp;</p><p>Immune system disorders</p><p><em>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>allergic reactions: urticaria, angioedema, erythema multiforme, exfoliative dermatitis, fever, arthralgia, anaphylactic shock with collapse and anaphylactoid reactions (asthma, purpura, gastrointestinal symptoms).</p><p><em>Not known:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>serum sickness. When treating syphilis, a Jarisch-Herxheimer reaction may occur as a result&nbsp;&nbsp; &nbsp;of bacteriolysis, characterised by fever, chills, general and focal symptoms. In</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>patients with dermatomycosis, para-allergic reactions may occur, as common antigenicity may exist between penicillins and dermatophyte metabolites.</p><p>&nbsp;</p><p>&nbsp;</p><p>Gastrointestinal disorders</p><p><em>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>diarrhoea, nausea</p><p><em>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>stomatitis and glossitis, vomiting</p><p><em>Not known:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>pseudomembranous colitis&nbsp; (see section 4.4).</p><p>&nbsp;</p><p>Hepatobiliary disorders</p><p><em>Not known:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>hepatitis, cholestasis</p><p>&nbsp;</p><p>&nbsp;</p><p>Renal and urinary disorders</p><p><em>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>nephropathy, interstitial nephritis</p><p>&nbsp;</p><p>General disorders and administration site conditions</p><p><em>Unknown:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>pain at the injection site, injection site infiltrates Hoign&eacute;- and Nicolau Syndrome</p><p>&nbsp;</p><p>Investigations</p><p><em>Common:</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; positive direct Coombs&rsquo; test.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; false-positive urinary protein determination when precipitation techniques are used (Folin- Ciocalteu-Lowry method, biuret method).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; false-positive urinary amino acid determination (ninhydrin method).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; simulation of pseudobisalbuminaemia when using electrophoresis methods to determine albumin.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; false-positive non-enzymatic urinary glucose detection and urobilinogen detection.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels when determining 17-ketosteroids in urine (when the Zimmermann reaction&nbsp;&nbsp; is used) (see section 4.4).</p><p>&nbsp;</p><p>In infants, local reactions are possible.</p><p>&nbsp;</p><p>It cannot be excluded that, in very rare cases and due to the povidone content, povidone may accumulate in the reticuloendothelial system (RES) or local deposits and foreign body granuloma may occur, which may be confused with tumors.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>At extremely high doses, penicillins can induce neuromuscular excitability or epileptiform seizures. If overdose is suspected, clinical monitoring and&nbsp; symptomatic&nbsp; measures&nbsp; are&nbsp; indicated.&nbsp; Benzylpenicillin can be haemodialysed.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacotherapeutic group</u></p><p>Antibacterials for systemic use, beta-lactamase sensitive penicillins. ATC code: J01CE08</p><p>&nbsp;</p><p><u>Mode of action</u></p><p>For benzathine benzylpenicillin, the mechanism of action is based on an inhibition of bacterial cell wall synthesis (during the growth phase) through a blockade of the penicillin-binding proteins (PBPs), such as transpeptidases. This results in a bactericidal action.</p><p>&nbsp;</p><p><u>Relationship between pharmacokinetics and pharmacodynamics</u></p><p>Efficacy largely depends on the length of time that the active substance level remains above the MIC of the pathogen.</p><p>&nbsp;</p><p><u>Resistance mechanisms</u></p><p>Resistance to benzathine benzylpenicillin can be due to the following mechanisms:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inactivation by beta-lactamases: benzathine benzylpenicillin is not beta-lactamase-resistant&nbsp; and therefore has no effect against beta-lactamase-producing bacteria (e.g. staphylococci or gonococci).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced affinity of PBPs for benzathine benzylpenicillin: the acquired resistance in pneumococci and a few other streptococci to benzathine benzylpenicillin is due to modifications of existing PBPs as a result of mutation. However, the formation of an additional PBP with reduced affinity for benzathine benzylpenicillin is responsible for resistance in methicillin (oxacillin)-resistant staphylococci.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In Gram-negative bacteria, inadequate penetration of benzathine benzylpenicillin through the outer cell wall can lead to insufficient PBP inhibition.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Benzathine benzylpenicillin can be actively transported from the cell by efflux pumps.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Benzathine benzylpenicillin is partially or completely cross-resistant to other penicillins and cephalosporins.</p><p>&nbsp;</p><p><u>Breakpoints</u></p><p>Testing of benzylpenicillin is performed using the standard dilution series. Results are evaluated on&nbsp; the basis of breakpoints for benzylpenicillin. The following minimum inhibitory concentrations have been established for susceptible and resistant germs:</p><p>&nbsp;</p><p>EUCAST (European Committee on Antimicrobial Susceptibility Testing) breakpoints</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Pathogen</strong></p></td><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Staphylococcus <em>spp.</em></strong></p></td><td style="vertical-align:top"><p>&pound; 0.12 mg/l</p></td><td style="vertical-align:top"><p>&gt; 0.12 mg/l</p></td></tr><tr><td style="vertical-align:top"><p><strong>Streptococcus <em>spp. (Groups A, B, C, G)</em></strong></p></td><td style="vertical-align:top"><p>&pound; 0.25 mg/l</p></td><td style="vertical-align:top"><p>&gt; 0.25 mg/l</p></td></tr><tr><td style="vertical-align:top"><p><strong>Streptococcus pneumoniae </strong><strong>#</strong></p></td><td style="vertical-align:top"><p>&pound; 0.06 mg/l</p></td><td style="vertical-align:top"><p>&gt; 2 mg/l</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Streptococci of the &ldquo;Viridans&rdquo; group</em></strong></p></td><td style="vertical-align:top"><p>&pound; 0.25 mg/l</p></td><td style="vertical-align:top"><p>&gt; 2 mg/l</p></td></tr><tr><td style="vertical-align:top"><p><strong>Neisseria meningitidis</strong></p></td><td style="vertical-align:top"><p>&pound; 0.06 mg/l</p></td><td style="vertical-align:top"><p>&gt; 0.25 mg/l</p></td></tr><tr><td style="vertical-align:top"><p><strong>Neisseria gonorrhoeae</strong></p></td><td style="vertical-align:top"><p>&pound; 0.06 mg/l</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Gram-negative anaerobes</em></strong></p></td><td style="vertical-align:top"><p>&pound; 0.25 mg/l</p></td><td style="vertical-align:top"><p>&gt; 0.5 mg/l</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Gram-positive anaerobes</em></strong></p></td><td style="vertical-align:top"><p>&pound; 0.25 mg/l</p></td><td style="vertical-align:top"><p>&gt; 0.5 mg/l</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Non-species-specific breakpoints*</em></strong></p></td><td style="vertical-align:top"><p>&pound; 0.25 mg/l</p></td><td style="vertical-align:top"><p>&gt; 2 mg/l</p></td></tr></tbody></table><p>*Based mainly on serum pharmacokinetics</p><p><strong># </strong>infections other than meningitis <u>Prevalence of acquired resistance</u></p><p>The prevalence of acquired resistance in individual species may vary geographically and over time. Thus, local information on the resistance situation is required, particularly for the adequate treatment of severe infections. If, based on the local resistance situation, the efficacy of benzylpenicillin is questionable, expert therapeutic advice should be obtained. Particularly in cases of serious infection&nbsp;&nbsp; or unsuccessful therapy, a microbiological diagnosis should be sought, with detection of the pathogen and its susceptibility to benzylpenicillin.</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Aerobic Gram-positive micro-organisms</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pyogenes</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus dysgalactiae </em>subsp. <em>equisimilis </em>&deg; (Group C &amp; G streptococci )</p></td></tr><tr><td style="vertical-align:top"><p>Streptococci of the &ldquo;Viridans&rdquo; group &deg; ^</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Other micro-organisms</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Treponema pallidum &deg;</em></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&deg; Information derived from published literature, clinical experience and therapeutic guidelines.</p><p>^ Collective name for a heterogeneous group of streptococci species. The resistance rate can vary depending on the streptococci species present.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetic data issued from the originator Retarpen dossier are old and information derived from them are limited. However published literature about benzathine benzylpenicillin, clinical experience and therapeutic guidelines can be taken into account.</p><p>&nbsp;</p><p><em>Absorption</em></p><p>Following intramuscular administration of Retarpen, the absorption of benzylpenicillin is very slow. Retarpen is the longest-acting depot penicillin. For many indications, 1-2 injections per month are sufficient. Consequently, the frequency of injections and the resultant local trauma are reduced. Peak plasma levels are reached 24 hours (children) or 48 hours (adults) post-injection.</p><p>&nbsp;</p><p><em>Distribution</em></p><p>About 55% of the administered dose is plasma protein-bound. When high-dose penicillin therapy is administered, therapeutically effective concentrations are reached even in poorly accessible tissues, such as heart valves, bone, as well as in the cerebrospinal fluid or in empyema, etc. Benzylpenicillin crosses the placenta. 10-30% of maternal plasma concentrations are found in the foetal circulation. High concentrations are also reached in the amniotic fluid. In contrast, transfer into milk is low. The volume of distribution is around 0.3-0.4 l/kg and about 0.75 l/kg in children. Plasma protein binding is approximately 55%.</p><p>&nbsp;</p><p><em>Biotransformation and elimination</em></p><p>Elimination largely takes place (50 - 80%) as unchanged substance via the kidneys (85 - 95%) and, to&nbsp; a lesser extent, in active form with the bile (about 5%).</p><p>The plasma half-life in adults with healthy kidneys is approximately 30 min.</p><p>&nbsp;</p><p><em>Kinetics in special patient groups</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Preterm and newborn infants: due to the immaturity of kidneys and liver at this age, the serum half-life is up to three hours (and more). The dosing interval must therefore be no shorter than 8 - 12 hours (depending on the degree of maturity).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elderly patients: elimination processes may also be delayed with advanced age. The dosage should therefore be adjusted to individual renal function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reproductive studies in mice, rats and rabbits revealed no negative effects on fertility or on the foetuses. No long-term studies on laboratory animals are available with regard to carcinogenicity, mutagenicity and fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Retarpen 600,000 IU - Powder and solvent for suspension for injection}: Povidone</p><p>Simethicone Sodium citrate Mannitol (E421).</p><p>1 vial of solvent contains: 5 ml water for injections Contains phospholipids from the soya beans</p><p>&nbsp;</p><p>Retarpen 1.2 MIU - Powder and solvent for suspension for injection:</p><p>Povidone</p><p>Simethicone Sodium citrate Mannitol (E421).</p><p>1 vial of solvent contains: 5 ml water for injections Contains phospholipids from the soya beans</p><p>&nbsp;</p><p>&nbsp;</p><p>Retarpen 2.4 MIU - Powder and solvent for suspension for injection:</p><p>Povidone</p><p>Simethicone Sodium citrate Mannitol (E421).</p><p>1 vial of solvent contains: 5 ml water for injections Contains phospholipids from the soya beans</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Data on compatibility are available with water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years

Chemical and physical in-use stability has been demonstrated for 24 hours at 25 °C.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage time and conditions prior to use are the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25 &deg;C.</p><p>&nbsp;</p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Solvent: Plastic vial made from polyethylene, nominal capacity 5 ml.</p><p>&nbsp;</p><p>Retarpen 600,000 IU powder and solvent for suspension for injection:</p><p>4&nbsp; ml clear glass vial, type III (Ph.Eur.), closed with halogenated butylrubber stopper and aluminium cap.</p><p>Packs with 1x powder and solvent for suspension for injection.</p><p>&nbsp;</p><p>Retarpen 1.2 MIU powder and solvent for suspension for injection:</p><p>5 ml clear glass vial, type III (Ph.Eur.), closed with halogenated butylrubber stopper and aluminium cap.</p><p>Packs with 1x or 100x powder and solvent for suspension for injection.</p><p>&nbsp;</p><p>&nbsp;</p><p>Retarpen 2.4 MIU powder and solvent for suspension for injection:</p><p>15 ml clear glass vial, type III (Ph.Eur.), closed with halogenated butylrubber stopper and aluminium cap.</p><p>Packs with 1x or 50 x powder and solvent for suspension for injection.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Retarpen 600,000 IU</u></p><p>For the IM injection, suspend the contents of the vial in at least 2 ml water for injections. This suspension should be shaken well for at least 20 seconds until suspended homogeneously and used immediately. If not used immediately shake the suspension again for at least 20 seconds until suspended homogeneously. The needle size should be at least 0.9 mm (needle no. 1). For single withdrawal only, use only freshly prepared suspensions. Prior to injection, intravascular&nbsp; administration should be excluded by aspiration. The injection site should be changed with repeated injections.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Retarpen 1.2&nbsp; MIU</u></p><p>For the IM injection, suspend the contents of the vial in at least 3 ml water for injections. This suspension should be shaken well for at least 20 seconds until suspended homogeneously and used immediately. If not used immediately shake the suspension again for at least 20 seconds until suspended homogeneously. The needle size should be at least 0.9 mm (needle no. 1). For single withdrawal only, use only freshly prepared suspensions. Prior to injection, intravascular&nbsp; administration should be excluded by aspiration. The injection site should be changed with repeated injections.</p><p>&nbsp;</p><p><u>Retarpen 2.4&nbsp; MIU</u></p><p>For the IM injection, suspend the contents of the vial in at least 5 ml water for injections. This suspension should be shaken well for at least 20 seconds until suspended homogeneously and used immediately. If not used immediately shake the suspension again for at least 20 seconds until suspended homogeneously. The needle size should be at least 0.9 mm (needle no. 1). For single withdrawal only, use only freshly prepared suspensions. Prior to injection, intravascular&nbsp; administration should be excluded by aspiration. The injection site should be changed with repeated injections.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                    Sandoz GmbH
    6250 Kundl
    Austria

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>